PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 1 year.

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the esophagus,
stomach, pancreas, colon, or rectum More than 30% positively immunoreactive to monoclonal
antibody CC49 in the metastatic or primary lesion OR TAG-72 antigen serum level greater
than 15 Measurable or evaluable unresectable or metastatic disease by CT scan

PATIENT CHARACTERISTICS: Age: 19 and over Performance status: ECOG 0-2 Life expectancy: At
least 3 months Hematopoietic: WBC greater than 3,500/mm3 Platelet count greater than
150,000/mm3 Hemoglobin greater than 10 g/dL Hepatic: Bilirubin less than 2.0 mg/dL ALT and
AST less than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases
present) PTT less than 37.0 seconds INR less than 2.0 Renal: Creatinine less than 2.0
mg/dL Other: No known allergy to murine immunoglobulin No iodine allergy No concurrent
illness that would preclude study Not pregnant or nursing Negative pregnancy test Fertile
patients must use effective contraception Must be ambulatory and able to comply with study
schedule

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.